Overview

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The PK and safety profiles to be examined following a single oral administration of TRK-100STP (120 μg) under fasting conditions to patients with renal impairment and to subjects with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Toray Industries, Inc
Treatments:
Beraprost
Epoprostenol